Redhill Biopharma (NASDAQ: RDHL) is one of 285 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its peers? We will compare Redhill Biopharma to related companies based on the strength of its institutional ownership, dividends, profitability, valuation, analyst recommendations, earnings and risk.
Earnings and Valuation
This table compares Redhill Biopharma and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Redhill Biopharma||$100,000.00||-$29.37 million||-1.83|
|Redhill Biopharma Competitors||$284.28 million||$34.29 million||133.68|
Redhill Biopharma’s peers have higher revenue and earnings than Redhill Biopharma. Redhill Biopharma is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Insider and Institutional Ownership
8.5% of Redhill Biopharma shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 17.1% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
This is a summary of recent ratings and recommmendations for Redhill Biopharma and its peers, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Redhill Biopharma Competitors||851||3198||11598||231||2.71|
Redhill Biopharma presently has a consensus price target of $25.00, indicating a potential upside of 405.05%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 45.62%. Given Redhill Biopharma’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Redhill Biopharma is more favorable than its peers.
Risk and Volatility
Redhill Biopharma has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500. Comparatively, Redhill Biopharma’s peers have a beta of 0.54, suggesting that their average stock price is 46% less volatile than the S&P 500.
This table compares Redhill Biopharma and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Redhill Biopharma Competitors||-5,277.49%||-435.66%||-39.69%|
Redhill Biopharma peers beat Redhill Biopharma on 7 of the 12 factors compared.
Redhill Biopharma Company Profile
Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools. Its clinical-stage pipeline includes: TALICIA (RHB-105), an oral combination therapy for the treatment of Helicobacter pylori infection; RHB-104, an oral combination therapy for the treatment of Crohn’s disease; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron; RHB-106; YELIVA (ABC294640); MESUPRON, and RIZAPORT (RHB-103).
Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.